Contents

Highlights of This Issue 1345

SPECIAL FEATURES

Editors’ Note

1347  Introducing New Strategies in…
James L. Abbruzzese,
Alexander M.M. Eggermont, and Eric H. Rubin

CCR New Strategies

1348  New Strategies in Kidney Cancer:
Therapeutic Advances through
Understanding the Molecular Basis
of Response and Resistance
Brian I. Rini

CCR Translations

1355  Does Lapatinib Work against
HER2-negative Breast Cancers?
Ingrid A. Mayer and Carlos L. Arteaga
See article p. 1486

Statistics in Clinical
Cancer Research

1358  Testing Clonal Relatedness of Tumors
Using Array Comparative Genomic
Hybridization: A Statistical Challenge
Irina Ostrovnya and Colin B. Begg

CCR Drug Updates

1368  Everolimus
Peter J. Houghton

Molecular Pathways

1373  HER3 Comes of Age: New Insights
into Its Functions and Role in
Signaling, Tumor Biology, and
Cancer Therapy
Marcia R. Campbell, Dhara Amin,
and Mark M. Moasser

1384  Cyclooxygenase-2 and Cancer
Treatment: Understanding the Risk
Should Be Worth the Reward
David G. Menter, Richard L. Schilsky,
and Raymond N. DuBois

HUMAN CANCER BIOLOGY

1391  High-Resolution Array Comparative
Genomic Hybridization in Sporadic
and Celiac Disease–Related Small
Bowel Adenocarcinomas
Begoña Diosdado, Tineke E. Boffart,
Russell Watkins, Beatriz Carvalho,
Bauke Ylstra, Marianne Tijssen,
Anne S. Bolijn, Fraser Lewis, Karen Maude,
Caroline Verbeke, Iris D. Nagtegaal,
Heike Grabsch, Chris J.J. Mulder, Phil Quirk,
Peter Howdle, and Gerrit A. Meijer

1402  Critical Role of Gα13 and Gα13 for
Human Small Cell Lung Cancer Cell
Proliferation In vitro and Tumor
Growth In vivo
Marius Grzelinski, Olaf Pinkenburg,
Thomas Büch, Maike Gold, Stefanie Stohr,
Hermann Kalwa, Thomas Gudermann,
and Achim Aigner

1416  Association of TGF-β1 Genetic
Variants with HPV16-positive
Oropharyngeal Cancer
Xiaoxiang Guan, Erich M. Sturgis,
Dapeng Lei, Zhensheng Liu,
Kristina R. Dahlstrom, Qingyi Wei,
and Guojun Li

1423  ZIP4 Regulates Pancreatic Cancer
Cell Growth by Activating
IL-6/STAT3 Pathway through Zinc
Finger Transcription Factor CREB
Yuqing Zhang, Uddalak Bharadwaj,
Craig D. Logsdon, Changyi Chen,
Qizhi Yao, and Min Li

1431  Neuroblastoma Progression
Correlates with Downregulation
of the Lymphangiogenesis
Inhibitor sVEGFR-2
Jürgen Becker, Helena Pavlakovic,
Fabian Ludewig, Fabiola Wilting,
Herbert A. Weich, Romulo Albuquerque,
Jayakrishna Ambati, and Jörg Wilting
CANCER THERAPY: PRECLINICAL

1442 Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy
Xin Dong, Jun Guan, John C. English, Julia Flint, John Yee, Kenneth Evans, Nevim Murray, Calum MacAulay, Raymond T. Ng, Peter W. Gout, Wan L. Lam, Janessa Laskin, Victor Ling, Stephen Lam, and Yuzhuo Wang

1452 Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non–Small Cell Lung Cancer
Stefanie Hammer, Anette Sommer, Iduna Fichtner, Michael Becker, Jana Rolff, Johannes Merk, Ulrich Klar, and Jens Hoffmann

1466 An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicity and Enhanced Therapeutic Efficacy without Oncogenicity
Zachary Hartman, Junping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Peplinski, Dong-Wan Kim, Wenle Xia, Neil Spector, Jeffrey Marks, William Barry, Amy Hobeika, Gayathri Devi, Andrea Amalfitano, Michael A. Morse, H. Kim Lyerly, and Timothy M. Clay

1478 Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma
Radhika Iyer, Audrey E. Evans, Xiaoxue Qi, Ruth Ho, Jane E. Minturn, Huaqing Zhao, Naomi Balamuth, John M. Maris, and Garrett M. Brodeur

1486 Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine Resistance

1498 Preclinical Investigation of PEGylated Tumor Necrosis Factor α in Dogs with Spontaneous Tumors: Phase 1 Evaluation
Douglas H. Thamm, Ilene D. Kurzman, Mike A. Clark, E.J. Ehrhart III, Susan L. Kraft, Daniel L. Gustafson, and David M. Vail

IMAGING, DIAGNOSIS, PROGNOSIS

1509 Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
Zev A. Wainberg, Adrian Anghel, Amrita J. Desai, Raul Ayala, Tong Luo, Brent Safran, Marlena S. Fejzo, J. Randolph Hecht, Dennis J. Slamon, and Richard S. Finn

1520 Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma
Toshiko Ishii, Takashi Ishida, Atae Utsunomiya, Atsushi Inagaki, Hiroki Yano, Hirokazu Komatsu, Shinsuke Iida, Kazunori Imada, Takashi Uchiyama, Shiro Akinaga, Kenya Shitara, and Ryuizo Ueda

1532 Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature
Kateleen De Preter, Joëlle Vermeulen, Benedikt Brors, Olivier Delattre, Angelika Egger, Matthias Fischer, Isabelle Janoueix-Lerosey, Cinzia Lavrin, John M. Maris, Jaime Mora, Akira Nakagawara, André Obertuer, Miki Ohira, Gudrun Schleiermacher, Alexander Schramm, Johannes H. Schulte, Qun Wang, Frank Westermann, Frank Speleman, and Jo Vandesompele

1542 Evaluation of Treatment-Associated Inflammatory Response on Diffusion-Weighted Magnetic Resonance Imaging and 2-[18F]-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography Imaging Biomarkers

1553 Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer

Melanoma MicroRNA Signature Predicts Post-Recurrence Survival

Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab
Howard M. Stern, Mary Padilla, Klaus Wagner, Lukas Amler, and Avi Ashkenazi

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendrogial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Martin J. van den Bent, Hendrikus J. Dubbink, Yannick Marie, Alba A. Brandes, Martin J.B. Taphoorns, Pieter Wesseling, Marc Frenay, Coes C. Tijsen, Denis Lacombe, Ahmed Idlbaib, Ronald van Marion, Johan M. Kros, Winand N.M. Dinjens, Thierry Gorlia, and Marc Sanson

Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma In situ Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
Josefine Becker, Lambert Skoog, Tommy Fonander, Bo Nordenskjöld, and Olle Stål

A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma
Hui Huang, Michael Menefee, Maureen Edgerly, Sen Zhuang, Herb Kotz, Marianne Poruchynsky, Lyn Mickley Huff, Susan Bates, and Tito Fojo

Diverse Patterns of T-Cell Response against Multiple Newly Identified Human Y Chromosome–Encoded Minor Histocompatibility Epitopes
Yishai Ofran, Haesook T. Kim, Vladimir Brusic, Loren Blake, Michael Mandrell, Catherine J. Wu, Stefanie Sarantopoulos, Roberto Bellucci, Derin B. Reskin, Robert J. Soiffer, Joseph H. Antin, and Jerome Ritz

The Journal of Clinical and Translational Research
The featured image is a lung adenocarcinoma stained with a novel, highly sensitive and specific antibody recognizing the ALK oncoprotein (brown staining) and counterstained with hematoxylin (blue staining). The tumor was shown to harbor a rearrangement of the ALK locus by genetic analysis. This assay will facilitate the routine identification of ALK-rearranged lung adenocarcinomas in clinical practice and detect lung cancers that may be responsive to ALK inhibitors. For details, see the article by Mino-Kenudson and colleagues on page 1561 of this issue.